Literature DB >> 2438490

Properties and mechanisms of production and action of endothelium-derived relaxing factor.

U Förstermann.   

Abstract

A brief review is given of the vasodilators that require an intact vascular endothelium to exert their relaxing effect. Then some major issues of the phenomenon of endothelium-dependent smooth muscle relaxation are discussed in more detail: The chemical structure of the endothelium-derived relaxing factor (EDRF), which mediates this type of vasodilation, is still unclear. There is agreement that EDRF is chemically unstable, but determinations of its biological half-life have yielded discrepant values (6-50 s). Recent evidence suggests that oxygen and/or activated oxygen species accelerate the evanescence of the factor. The biochemical mechanisms involved in the production of EDRF are still largely unknown. Both stimulators of phospholipase A2 and inhibitors of lysolecithin acyltransferase were found to induce EDRF-mediated relaxation, while several phospholipase inhibitors block these relaxations. These findings suggest that cleavage of phospholipids (and formation of free fatty acids and lysophosphatides) play an important role in EDRF production. EDRF-mediated relaxations are associated with increased levels of cyclic GMP in vascular smooth muscle cells. Endothelial cells were found to produce a factor that directly stimulates the enzymatic activity of soluble guanylate cyclase. This stimulating factor is likely to be identical with EDRF. The significance of the endothelium-dependent relaxing mechanism in resistance vessels is still largely unclear. In the blood-perfused hind limb of the rabbit, two irreversible inhibitors of endothelium-dependent vasodilation (gossypol and p-bromophenacyl-bromide) blocked the vasodilation induced by the endothelium-dependent agent acetylcholine, but not the response to the endothelium-independent vasodilator prostaglandin E1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2438490     DOI: 10.1097/00005344-198600101-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Inhibition of vascular smooth muscle relaxation by LY83583.

Authors:  E Malta; P S Macdonald; G J Dusting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-04       Impact factor: 3.000

2.  Selective inhibition by gossypol of endothelium-dependent relaxations augments relaxations to glyceryl trinitrate in rabbit coeliac artery.

Authors:  U Alheid; C Dudel; U Förstermann
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

3.  Heterogeneity of the response of venous smooth muscle to arterial endothelium-derived relaxing factor (EDRF) in respect of the role of nitric oxide.

Authors:  Y P Vedernikov; T Gräser; N Tiedt; A M Vikhert
Journal:  Basic Res Cardiol       Date:  1988 Mar-Apr       Impact factor: 17.165

Review 4.  Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters.

Authors:  L J Ignarro
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

Review 5.  Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.

Authors:  L J Ignarro; G Ross; J Tillisch
Journal:  West J Med       Date:  1991-01

6.  Effect of methylguanidine on rat blood pressure: role of endothelial nitric oxide synthase.

Authors:  R Sorrentino; A Pinto
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

7.  L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells.

Authors:  Joy N Jones Buie; Dorea Pleasant Jenkins; Robin Muise-Helmericks; Jim C Oates
Journal:  Lupus Sci Med       Date:  2019-02-19

8.  Prolonged exposure of chromaffin cells to nitric oxide down-regulates the activity of soluble guanylyl cyclase and corresponding mRNA and protein levels.

Authors:  Rut Ferrero; Magdalena Torres
Journal:  BMC Biochem       Date:  2002-09-12       Impact factor: 4.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.